CLINICAL TRIAL: NET-PD LONG-TERM STUDY -1 (LS- 1)

临床试验：NET-PD 长期研究 -1 (LS- 1)

• 批准号: 7731295
• 负责人: LEWIS R SUDARSKY
• 金额: $ 0.08万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731295
• 关键词: Caring; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Creatine; Disease Progression; Funding; Grant; Institution; Longitudinal Studies; Measures; Medical; Outcome; Parkinson Disease; Placebos; Research; Research Personnel; Resources; Source; Sum; Testing; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary study aim of this trial is to compare the effect of creatine with placebo on progression of Parkinson's disease over 5 years. The primary outcome will compare the mean rank sum of five measures in the creatine group versus the placebo group against a background of dopaminergic therapy and best medical care. The research hypothesis is that the group being treated with creatine will show less disease progression by 5 years than the group on placebo as evaluated by a Global Statistical Test.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该试验的主要研究目的是比较肌酸与安慰剂在 5 年内对帕金森病进展的影响。 主要结局将在多巴胺能治疗和最佳医疗护理的背景下比较肌酸组与安慰剂组五项指标的平均排名总和。 研究假设是，根据全球统计测试的评估，使用肌酸治疗的组将比使用安慰剂的组在 5 年内表现出更少的疾病进展。